Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Share-based Compensation (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Share-based Compensation for 16 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 20.19% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2025, down 23.79% year-over-year, with the annual reading at $9.5 million for FY2025, 23.79% down from the prior year.
  • Share-based Compensation hit $2.3 million in Q4 2025 for Vanda Pharmaceuticals, up from $2.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.8 million in Q1 2022 to a low of $2.1 million in Q2 2025.
  • Historically, Share-based Compensation has averaged $3.4 million across 5 years, with a median of $3.4 million in 2023.
  • Biggest five-year swings in Share-based Compensation: rose 26.03% in 2021 and later decreased 29.58% in 2025.
  • Year by year, Share-based Compensation stood at $3.8 million in 2021, then increased by 0.24% to $3.8 million in 2022, then fell by 13.48% to $3.3 million in 2023, then decreased by 12.53% to $2.9 million in 2024, then decreased by 20.19% to $2.3 million in 2025.
  • Business Quant data shows Share-based Compensation for VNDA at $2.3 million in Q4 2025, $2.1 million in Q3 2025, and $2.1 million in Q2 2025.